Anxo Pharmaceutical Co., Ltd.

NT$21.10As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6677Healthcare
Country Taiwan
PE (Fwd) •••
TSR 8Y CAGR (8.99%)
Div yield 1.89%
ROE (1.99%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.27
PE TTM —
TSR TTM (15.09%)
Mkt cap NT$1.182B
ROIC (1.69%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$27
26.28%
7.92%
Hold 11|0|1|8|10
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.33
0.36
0.36
0.35
5.70%
10.83%
8.49%
4.99%
RevenueNT$M
108.1
108.4
112.7
114.3
0.75%
0.66%
4.74%
3.22%
Peers (US$35.46M)
Cap (US$)
PE
32.68M
—
34.82M
—
Capital
TTM
5Y
10Y
Leveragex
2.506
0.077
0.080
EBIT/Intx
0.661
0.390
0.420
Own earn%
5.26
(92.00)
(96.68)
Sh yield%
36.57
33.85
34.80
Owners
Insiders/Inst%
1.69
54.46
Short interest%
3.49
SBC / revenue%
4.29
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
0–5
$1 testx
—
Incr. ROIC%
14